Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015 Now Available at iData Insights Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015, provides an overview of the Cytomegalovirus (HHV-5) Infectionss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by 1
identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=173359/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173359/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015 Table of Contents Introduction 8 Global Markets Direct Report Coverage 8 Cytomegalovirus (HHV-5) Infections Overview 9 Therapeutics Development 10 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11 Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12 Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 15 Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20 Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23 Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 24 AIMM Therapeutics B.V. 24 Altor BioScience Corporation 25 Applied Immune Technologies Ltd 26 Astellas Pharma Inc. 27
2
Atara Biotherapeutics, Inc. 28 Bionor Pharma ASA 29 Biotest AG 30 CAP-CMV GmbH 31 Cell Medica Limited 32 Chimerix, Inc. 33 China Biologic Products, Inc. 34 CyTuVax B.V. 35 GlaxoSmithKline Plc 36 Hookipa Biotech AG 37 Humabs BioMed SA 38 iQur Limited 39 Kadmon Corporation, LLC 40 Lead Discovery Center GmbH 41 Merck & Co., Inc. 42 Microbiotix, Inc. 43 Novartis AG 44 Pfizer Inc. 45 Phoenix Biotechnology, Inc. 46 Savoy Pharmaceuticals, Inc. 47 Trellis Bioscience, Inc. 48 Vakzine Projekt Management GmbH 49 VBI Vaccines Inc. 50 Vical Incorporated 51 Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 3
Assessment by Target 54 Assessment by Mechanism of Action 56 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 AL-18 - Drug Profile 62 Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 63 Antibody for Human Cytomegalovirus Infection - Drug Profile 64 Antiviral TCR-Ck - Drug Profile 65 Antiviral TCR-Ig - Drug Profile 66 ASP-0113 - Drug Profile 67 brincidofovir - Drug Profile 69 BT-084 - Drug Profile 72 CAPCMV-001 - Drug Profile 73 Cell Therapy 3 For CMV - Drug Profile 74 Cell Therapy for CMV Infections - Drug Profile 75 Cell Therapy for Cytomegalovirus (HHV-5) Infections - Drug Profile 76 Cell Therapy for Cytomegalovirus Infections - Drug Profile 77 Cell Therapy for Cytomegalovirus Infections - Drug Profile 78 Cell Therapy for Cytomegalovirus Infections and GBM - Drug Profile 79 Cell Therapy for Infectious Disease - Drug Profile 80 Cell Therapy for Infectious Diseases - Drug Profile 81 Cell Therapy for Viral Infections Post-HSCT - Drug Profile 82 Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 83 Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 85 Cellular Immunotherapy for Viral Infections - Drug Profile 86
4
CMX-669 - Drug Profile 87 CSJ-148 - Drug Profile 88 CyMVectin - Drug Profile 89 Cytomegalovirus (virus like particles) vaccine - Drug Profile 90 Cytomegalovirus vaccine - Drug Profile 91 Cytomegalovirus vaccine - Drug Profile 92 Cytomegalovirus vaccine - Drug Profile 93 Cytomegalovirus vaccine - Drug Profile 94 Cytomegalovirus vaccine 1 - Drug Profile 95 Cytomegalovirus vaccine 2 - Drug Profile 97 Cytovir-CMV - Drug Profile 98 Dendritic Cell Therapyto Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 100 Drug for Cytomegalovirus - Drug Profile 101 filociclovir - Drug Profile 102 Gene Therapy for Cytomegalovirus Infections - Drug Profile 104 HB-101 - Drug Profile 105 LDC-4297 - Drug Profile 106 letermovir - Drug Profile 107 maribavir - Drug Profile 108 MBX-2168 - Drug Profile 110 Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 111 Monoclonal Antibody for HCMV Infections - Drug Profile 112 Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 113 RBT-301 - Drug Profile 114 Recombinant Peptide for Infectious Diseases - Drug Profile 115 RKP-00156 - Drug Profile 116 Small Molecule 1 for Human Cytomegalovirus Infection - Drug Profile 117 5
Small Molecule 2 for Human Cytomegalovirus Infection - Drug Profile 118 Small Molecule 3 for Human Cytomegalovirus Infection - Drug Profile 119 Small Molecules for CMV Infections - Drug Profile 120 Small Molecules for Viral Infections - Drug Profile 121 Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 122 Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 123 Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 124 Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 125 TRL-345 - Drug Profile 126 V-160 - Drug Profile 127 Vacc-CMV - Drug Profile 128 Vaccine for Cytomegalovirus Infection and Glioblastoma Multiforme - Drug Profile 129 VBI-1501A - Drug Profile 130 Viralym-C - Drug Profile 131 Viroprev - Drug Profile 132 VPM-2001 - Drug Profile 133 Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 134 Cytomegalovirus (HHV-5) Infections - Dormant Projects 154 Cytomegalovirus (HHV-5) Infections - Discontinued Products 158 Cytomegalovirus (HHV-5) Infections - Product Development Milestones 159 Featured News & Press Releases 159 Appendix 168 Methodology 168 Coverage 168 Secondary Research 168 Primary Research 168 6
Expert Panel Validation 168 Contact Us 168 Disclaimer 169
Read More http://www.idatainsights.com/reports-landing-page.php?id=173359/cytomegalovirushhv-5-infections-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
7